- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 23
The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of October 23.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 23.
Number 5: Novartis credits stronger-than-expected sales of its biosimilars for strong third-quarter net income.
Number 4: Etanercept has been shown to significantly reduce overall healthcare utilization for patients with rheumatoid arthritis, especially for patients who are highly compliant with therapy.
Number 3: New evidence suggests that anti—tumor necrosis factor agents could be repurposed to treat depression that is unresponsive to existing therapies.
Number 2: The FDA has released new educational materials on biosimilars. The resources, geared toward clinicians, include webinars, staff presentations, graphics, and sharable social media assets.
Number 1: The RAND corporation has released a new report on biosimilars, estimating that the United States could save $54 billion over the next 10 years by using biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
